Matches in SemOpenAlex for { <https://semopenalex.org/work/W2365651330> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2365651330 abstract "The progressive development of amyloid and tau deposits, synaptic dysfunction and cognitive decline are well characterised in 3xTg-AD mice. 3xTg-AD mice thus provide an excellent model for testing the potential benefit of new disease-modifying treatments. Organotypic brain slice culture models provide an alternative to early stage in vivo testing since they recapitulate key disease features, and provide a higher throughput platform for drug screening. Here, we describe a novel organotypic 3xTg-AD brain slice culture model, and highlight its potential for researching the effects of disease-modifying agents such as the amyloid-binding tetra (ethylene glycol) derivative of benzothiazole aniline, BTA-EG4. Organotypic brain slice cultures were prepared from neonatal 3xTg-AD and WT mice and cultured for several weeks. Slices were characterised for changes in total and phosphorylated tau and APP processing, with respect to aged mice. Slice cultures were treated with disease-modifying agents such as BTA-EG4 and the effects on abnormal tau species and APP processing were determined. Organotypic brain slice cultures from 3xTg-AD mice show elevated tau phosphorylation and the presence of high molecular weight tau species soon after culture, in comparison to slice cultures from WT mice. The novel amyloid-binding agent BTA-EG4, previously reported to reduce levels of beta-amyloid (Aβ), increase dendritic spine density and ameliorate cognitive decline in mouse models of AD, was found here to also reduce the presence of abnormal tau species and other neurodegenerative features in 3xTg-AD brain slice cultures. We have successfully established a method to produce and maintain brain slices from 3xTg-AD mice in culture long-term. Our observations of rapid development of tau pathology in 3xTg-AD brain slices highlights the potential of this model as a more rapid and reliable in vitro method for drug screening prior to in vivo testing. Indeed, we demonstrate here novel tau-directed effects of BTA-EG4. The precise mode of action of this drug is currently being explored. Our findings support the further exploration of BTA-EG4 as a candidate therapeutic for Alzheimer's disease." @default.
- W2365651330 created "2016-06-24" @default.
- W2365651330 creator A5006726665 @default.
- W2365651330 creator A5015512770 @default.
- W2365651330 creator A5039912343 @default.
- W2365651330 date "2015-07-01" @default.
- W2365651330 modified "2023-10-16" @default.
- W2365651330 title "P3-054: The amyloid-binding agent bta-eg4 reduces pathological tau species in a novel organotypic 3xTg-AD brain slice culture model that recapitulates key in vivo degenerative phenotypes" @default.
- W2365651330 doi "https://doi.org/10.1016/j.jalz.2015.06.921" @default.
- W2365651330 hasPublicationYear "2015" @default.
- W2365651330 type Work @default.
- W2365651330 sameAs 2365651330 @default.
- W2365651330 citedByCount "0" @default.
- W2365651330 crossrefType "journal-article" @default.
- W2365651330 hasAuthorship W2365651330A5006726665 @default.
- W2365651330 hasAuthorship W2365651330A5015512770 @default.
- W2365651330 hasAuthorship W2365651330A5039912343 @default.
- W2365651330 hasConcept C102230213 @default.
- W2365651330 hasConcept C104317684 @default.
- W2365651330 hasConcept C127716648 @default.
- W2365651330 hasConcept C141035611 @default.
- W2365651330 hasConcept C142724271 @default.
- W2365651330 hasConcept C169760540 @default.
- W2365651330 hasConcept C185592680 @default.
- W2365651330 hasConcept C207001950 @default.
- W2365651330 hasConcept C2777633098 @default.
- W2365651330 hasConcept C29694410 @default.
- W2365651330 hasConcept C529278444 @default.
- W2365651330 hasConcept C54355233 @default.
- W2365651330 hasConcept C55493867 @default.
- W2365651330 hasConcept C71924100 @default.
- W2365651330 hasConcept C86803240 @default.
- W2365651330 hasConcept C95444343 @default.
- W2365651330 hasConcept C98274493 @default.
- W2365651330 hasConceptScore W2365651330C102230213 @default.
- W2365651330 hasConceptScore W2365651330C104317684 @default.
- W2365651330 hasConceptScore W2365651330C127716648 @default.
- W2365651330 hasConceptScore W2365651330C141035611 @default.
- W2365651330 hasConceptScore W2365651330C142724271 @default.
- W2365651330 hasConceptScore W2365651330C169760540 @default.
- W2365651330 hasConceptScore W2365651330C185592680 @default.
- W2365651330 hasConceptScore W2365651330C207001950 @default.
- W2365651330 hasConceptScore W2365651330C2777633098 @default.
- W2365651330 hasConceptScore W2365651330C29694410 @default.
- W2365651330 hasConceptScore W2365651330C529278444 @default.
- W2365651330 hasConceptScore W2365651330C54355233 @default.
- W2365651330 hasConceptScore W2365651330C55493867 @default.
- W2365651330 hasConceptScore W2365651330C71924100 @default.
- W2365651330 hasConceptScore W2365651330C86803240 @default.
- W2365651330 hasConceptScore W2365651330C95444343 @default.
- W2365651330 hasConceptScore W2365651330C98274493 @default.
- W2365651330 hasIssue "7S_Part_14" @default.
- W2365651330 hasLocation W23656513301 @default.
- W2365651330 hasOpenAccess W2365651330 @default.
- W2365651330 hasPrimaryLocation W23656513301 @default.
- W2365651330 hasRelatedWork W1516968396 @default.
- W2365651330 hasRelatedWork W2069638680 @default.
- W2365651330 hasRelatedWork W2071476973 @default.
- W2365651330 hasRelatedWork W2102489568 @default.
- W2365651330 hasRelatedWork W2164246885 @default.
- W2365651330 hasRelatedWork W2185890143 @default.
- W2365651330 hasRelatedWork W2593242044 @default.
- W2365651330 hasRelatedWork W2748952813 @default.
- W2365651330 hasRelatedWork W2899084033 @default.
- W2365651330 hasRelatedWork W4323517789 @default.
- W2365651330 hasVolume "11" @default.
- W2365651330 isParatext "false" @default.
- W2365651330 isRetracted "false" @default.
- W2365651330 magId "2365651330" @default.
- W2365651330 workType "article" @default.